cardioplegia

(redirected from Cardioplegic solutions)
Also found in: Dictionary.

cardioplegia

 [kahr″de-o-ple´jah]
arrest of myocardial contraction, as by use of chemical compounds or cold in cardiac surgery. adj., adj cardiopleg´ic.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

car·di·o·ple·gi·a

(kar'dē-ō-plē'jē-ă),
1. Paralysis of the heart.
2. An elective stopping of cardiac activity temporarily by injection of chemicals, selective hypothermia, or electrical stimuli.
[cardio- + G. plēgē, stroke]
Farlex Partner Medical Dictionary © Farlex 2012

car·di·o·ple·gi·a

(kahr'dē-ō-plē'jē-ă)
1. Paralysis of the heart.
2. An elective temporary cessation of cardiac activity by injection of chemicals, selective hypothermia, or electrical stimuli and used to perform surgery on the heart.
[cardio- + G. plēgē, stroke]
Medical Dictionary for the Health Professions and Nursing © Farlex 2012

cardioplegia

Deliberate temporary stopping of the heart beat (contractions) in the course of heart surgery, either by cooling or by means of drugs.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
Mentioned in ?
References in periodicals archive ?
Thomas' cardioplegic solutions. Substrate (mM) [HTK.sup.*+] [St.
We hypothesized that a single dose of histidine-tryptophan-ketoglutarate (HTK) could offer superior myocardial protection than cold crystalloid cardioplegic solution in these high-risk patients.
The myocardial protection of HTK cardioplegic solution on the long-term ischemic period in pediatric heart surgery.
The role of cardioplegic solution buffering in myocardial protection.
Histidine-tryptophan-ketoglutarate solution decreases mortality and morbidity in high-risk patients with severe pulmonary arterial hypertension associated with complex congenital heart disease: an 11-year experience from a single institution
The effect of different cardioplegic solutions on NO release from the coronary vasculature during cardiopulmonary bypass in patients with type II diabetes has not been characterized.
Although the release of ET-1 during CPB in diabetic population has been studied, the effect of CPB and cardioplegic solutions on NO production in the same patient population is not clear.
Effects of different cardioplegic solutions on nitric oxide release from coronary vasculature in diabetic patients undergoing coronary artery bypass surgery/Iki degisik kardiyoplejik solusyonun koroner arter baypas cerrahisi geciren diyabetik hastalarda koroner yataktan salinan nitrik oksit seviyelerine etkileri
Metabolic responses are further affected by anesthesia, heparin, protamine, the cardioplegic solution, and activation of complement.
Meeting the special needs of the open heart surgery patient

Medical browser ?
Full browser ?